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Abstract
Background: FAS/FASL promoter variants are considered in altering transcriptional activity of those genes and
consequently alter regulation of cell death. However, no studies have investigated whether tumor sites contribute
to the association between FAS/FASL polymorphisms and risk for second primary malignancy (SPM).
Method: In this study, FAS670 A > G, FAS1377 G > A, FASL124 A > G, and FASL844C > T polymorphisms were genotyped
in 752 OPC and 777 non-OPC patients. Both univariate and multivariable cox proportional hazard models were used to
assess the associations.
Results: The univariate and multivariable analyses showed that patients with index OPC and FASL844 CT/TT genotype
had significantly increased risk of SPM (cHR, 2.5; 95 % CI, 1.1–5.8, P = 0.043 and aHR, 2.7; 95 % CI, 1.2–6.0, P = 0.032)
compared with those with FASL844 CC genotype as the reference group, while index non-OPC patients with FAS670
AG/GG and FasL844 CT/TT genotypes had significantly increased risk of SPM (cHR, 2.2 and 1.8; 95 % CI, 1.2–5.7
and 1.1–3.2; and P = 0.04 and 0.041, respectively and aHR, 2.4 and 1.7; 95 % CI, 1.1–5.1 and 1.0-3.0; and P = 0.043
and 0.049, respectively) compared with their corresponding AA and CC genotypes . Moreover, patients carrying
more FAS/FASL variants significantly increased risk of SPM among index non-OPC patients. The stratified analysis
showed that smoking status differently modified the associations between FAS/FASL polymorphisms and risk of
SPM among index non-OPC from OPC patients.
Conclusion: These results suggested that FAS/FASL polymorphisms might significantly modify SPM risk among
patients with SCCHN in a tumor site-specific manner.
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Background
The squamous cell carcinomas of the head and neck
(SCCHN) arise in the upper aerodigestive tract including
the oral cavity, the oropharynx, the hypopharynx, and
the larynx [1]. The SCCHN are associated with a high
incidence rate of second primary malignancy (SPM), for
which the risk remains at a substantially high during the
lifespan of the patients [2–5]. Although we have seen
the declining trend of overall SCCHN incidence, the de-
crease in incidence of SPM is heterogeneous across all
tumor sites within the head and neck regions.
The oropharyngeal cancer (OPC) has the features of
an aggressive local tumor, with a moderately high recur-
rence rate, high frequency of SPM, and high frequency
of medical comorbidities [6]. While the incidence of
OPC is increasing, the attributable risk to SPM in patients
with index OPC has declined since the 1990s. Moreover,
the incidence of HPV-positive OPC cases increases among
OPC patients, whereas the oropharynx is the subsite with
the lowest SPM risk [3, 7–9]. Therefore, HPV is highly
relevant to the SPM rates in OPC patients. The nonoro-
pharyngeal cancer (non-OPC) includes tumors which
occur in oral cavity, larynx, and hypopharynx. Compared
with patients with OPC, the patients with non-OPC have
the consistently high risk of SPM [3].
The SPMs in OPC and non-OPC patients still remain
one of major factors that contribute to the poor progno-
sis of these patients [2, 10–12]. Cigarette smoking and
alcohol use have been found to be associated with the
risk of SPM [13, 14], while only a small proportion of
these patients develop a SPM, suggesting that there is a
person to person variation in genetic susceptibility to
SPM among the patients [2]. We have previously re-
ported that genetic polymorphisms involved in several
molecular pathways were associated with the risk of
SPM after primary SCCHN, such as carcinogen metabol-
ism, DNA repair, and cell cycle control [12, 15–21].
Apoptosis is the physiological mechanism of pro-
grammed cell death that plays an important role in diverse
biological processes such as development, homeostasis of
tissues, and elimination of cancer cells [22, 23]. The ac-
quired ability to resist apoptotic stimuli is one of the pri-
mary characteristics of a malignant cell, and abnormal
regulation of apoptosis is a key mechanism in the develop-
ment of cancer [24]. FAS is a cell surface receptor that can
interact with FASLG to trigger apoptosis [25]. Therefore,
FAS/FASLG pathway plays an important role in regulation
of apoptosis and maintenance of cellular homeostasis, and
genetic alteration of FAS/FASLG signaling pathway may
result in immune escape, and thus tumorigenesis includ-
ing SPM.
The two polymorphisms identified in the FAS promoter
region: FAS1377 G >A rs2234767 and FAS670 A >G
rs1800682 result in decreased promoter activity and de-
creased FAS gene expression in consequence [26]. An-
other two polymorphisms in FASL promoter: FASL844
C > T rs763110 and FASL 124 A >G rs5030772 may in-
crease basal expression of FASL, resulting in aberrant
FASL expression and subsequently increased susceptibility
to cancer [26, 27].
Although we have previously reported a study on asso-
ciation of these functional polymorphisms with SPM risk
among SCCHN patients, showing that FAS670 and
FASL844 polymorphisms were associated with a signifi-
cantly increased risk for SPM in overall SCCHN patients
[28], no studies have evaluated the associations between
these polymorphisms with risk of SPM in different
tumor sites of SCCHN. Since FAS/FASL pathway plays a
critical role in apoptosis, this study might provide novel
information for prognosis and secondary as well as ter-
tiary cancer prevention of these patients. Therefore, we
evaluated the associations between each or in combin-
ation of the four FAS/FASL genetic variants and risk of




All the participants with incident cases were consecu-
tively recruited between May 1995 and December 2010
through the Head and Neck Center at The University of
Texas, M.D. Anderson Cancer Center. The inclusion cri-
teria for cases were: (1) newly diagnosed, histopatho-
logically confirmed squamous cell carcinomas of the oral
cavity, oropharynx, hypopharynx, or larynx; (2) no his-
tory of treatment with either chemotherapy or radiation
therapy treatment; and (3) patients with previous history
of cancer excepting non-melanoma skin cancer, distant
metastases at presentation, primary tumors of the naso-
pharynx or sinoasal tract, primary tumors outside the
upper aerodigestive tract, cervical metastases of un-
known origin, or histopathologic diagnoses other than
squamous cell carcinoma were excluded. The study re-
ceived approval from the institutional review boards of
both MD Anderson and Kelsey-Seybold, and all study
subjects signed an informed consent when approached
for recruitment. All patients completed a standardized
questionnaire including demographic, exposure informa-
tion (including tobacco and alcohol), work history, and
family history data, and donated a blood sample for
genotyping data at the time of recruitment. Participants
who were not able to provide their blood samples during
the recruitment were excluded in the analysis.
Patients were monitored through their treatment and
post-treatment course with regularly scheduled clinical
and radiographic examinations. SPMs were distinguished
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from local recurrences based on modified criteria of
Warren and Gates [29]. Second lesions with different his-
tophathologic type and/or occurring >5 years following
treatment for the primary tumor and/or clearly separated
by normal epithelium based on clinical and radiographic
assessment were considered SPM. The second lesion was
classified as a local recurrence rather than a SPM if there
was discrepancy or differing opinion about the origin of
the tumor. Pulmonary lesions were considered SPM if
they had a non-squamous histology or if they were iso-
lated squamous lesions >5 years from initial SCCHN and
felt to be SPM by the thoracic oncologist and thoracic sur-
geon. Medical record review for follow-up status of all
patients was performed under supervision of the staff
head and neck surgeon. Patients who had smoked >100
cigarettes in their lifetimes were categorized as “ever-
smokers,” and others were “never-smokers.” Similarly,
subjects who had drunk alcoholic beverages at least once
a week for >1 year previously were as “ever-drinkers,” and
others were “never-drinkers.” Clinical data were obtained
at initial presentation and through follow-up examinations
and included overall stage at presentation of index tumor,
site of index tumor, and treatment. Index cancer stages
were then dichotomized into the early stage (clinical stage
I and II) and late stage (III and IV). Types of treatment
were categorized into three groups: surgery only, surgery
and chemotherapy and/or radiotherapy, and chemother-
apy and/or radiotherapy.
Genotyping
Genomic DNA was extracted from a leukocyte cell pellet
for FAS/FASL genotyping, which was obtained from the
buffy coat by the centrifugation of 1 mL of whole blood,
using the Qiagen DNA Blood Mini Kit (Qiagen Inc.) in
accordance with the manufacturer’s instructions. The
genotyping of the four SNPs was performed as previ-
ously described [26]. Moreover, there was 100 % con-
cordance when we randomly selected at least 10 % of
the random samples to retest for confirmation of the
original findings.
Statistical analysis
The statistical analyses were performed by Intercooled
Stata 13.0 (Stata Inc., College Station, TX). All tests were
two-sided, and a P-value < 0.05 was considered the cutoff
for statistical significance. All statistical tests were proc-
essed in patients with index OPC and in patients with
index non-OPC separately. SPM was considered as the
primary endpoint of this study. The Student’s t tests
were used to compare the mean age and follow-up time
of the patients who developed a SPM and those who did
not. The differences in ethnicity, sex, smoking and alco-
hol status, index tumor stage, treatment, and genotype
distributions between the two groups were evaluated
using the chi-squared test. Time-to-event was calculated
from the date of diagnosis of the index cancer patients
to the date of SPM occurrence. Patients who did not
know to have an event at the date of last contact, or
who died were censored. The associations between indi-
vidual epidemiological risk factors, clinical characteris-
tics including index tumor stage and treatment variables,
and time to the occurrence of SPMs, were initially
assessed using univariate Cox proportional hazards re-
gression models. The data were consistent with the as-
sumptions of the Cox proportional hazards regression
model from the examination of Kaplan-Meier survival
curves. In the univariate and multivariable analyses
(adjusted by age, gender, ethnicity, smoking and drinking
status, index cancer stage, and treatment), the associa-
tions were calculated using hazard ratios (HR) and their
95 % confidence intervals (CI) for the development of
the SPMs. For each polymorphism, the wild-type geno-
type was set as the reference group; the variant geno-
types of each polymorphism were combined. In addition,
for the combined analysis of the four polymorphisms,
the patients with 0–2 risk genotypes as the low-risk
group were used as the reference group in comparison




The study subjects were a cohort of 1529 patients, includ-
ing 752 patients with index OPC and 777 patients with
non-OPC. There were significant differences in the median
age at diagnosis and follow-up time between index OPC
patients and index non-OPC patients (54 years vs. 59 years;
P = 0.0011; 51.3 months; 63.8 months; P = 0.00012, respect-
ively), and patients who developed SPMs were more likely
to be index non-OPC (P = 0.001) when we compared the
patients with and without SPM. Our data indicated
that patients with index OPC had a lower rate of SPM
compared to those with non-OPC (approximately 6 %
vs. 11 %). Table 1 shows the demographics, risk factors,
and clinical variables for the 752 patients with index
OPC and 777 patients with non-OPC. For OPC pa-
tients, there were 710 (94.4 %) patients who did not
develop SPM and 42 (5.6 %) patients who developed
SPMs. The median age at diagnosis was 54 years
(range, 28–84 years). In this patient cohort, we found
age and smoking were significantly associated with
SPM development (P = 0.004 for age and P = 0.010 for
smoking), while we did not observe significant differ-
ences between patients with and without SPMs, re-
garding other characteristic variables. For the patients
with index non-OPC, there were 695 (89.4 %) patients
who did not develop SPMs and 82 (10.9 %) patients
who developed SPMs. The median age at diagnose was
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59 years (range, 18–94 years). We found that the pa-
tients who developed SPMs were more likely to be
older (P = 0.024), ever smokers (P = 0.037), ever alcohol
user (P = 0.005), non-Hispanic white (P = 0.028), and
late disease stage (P = 0.035). However, these patients
had no significant differences in developing SPMs, re-
garding sex (P = 0.170) and treatment (P = 0.111).
FAS/FASL polymorphisms and risk of SPM after index OPC
and non-OPC
Table 2 shows both univariate and multivariable analyses
on SPM risk associated with FAS/FASL polymorphisms
after index OPC and non-OPC. For multivariable ana-
lysis, the estimates of associations were adjusted by age,
gender, ethnicity, smoking and drinking status, index
cancer stage, and treatment. The patients with OPC and
FASL844 CT/TT genotypes were found to significantly
increase the risk of SPM compared with those with the
corresponding CC genotype (cHR, 2.5, 95 % CI, 1.1–5.8,
P = 0.043 and aHR, 2.7, 95 % CI, 1.2–6.0, P = 0.032,
respectively); however, such a significant association was
not observed for other polymorphisms. In contrast, the
non-OPC patients carrying FAS670 AG/GG and
FASL844 CT/TT variant genotypes had approximately
2.5 times (cHR, 2.2, 95 % CI, 1.2–5.7, P = 0.048 and
aHR, 2.4, 95 % CI, 1.1–5.1, P = 0.043, respectively) and
2.0 times (cHR, 1.8, 95 % CI, 1.1–3.2, P = 0.041 and
aHR, 1.7, 95 % CI, 1.0–3.0, P = 0.049, respectively) in-
creased risk of SPMs compared with those with the cor-
responding AA or CC genotypes, respectively.
Associations of the combined FAS/FASL variant genotypes
with risk of SPMs after index OPC and non-OPC
As shown in Table 3, we performed the combined ana-
lysis of all 4 SNPs to focus on potentially modifying ef-
fect of the combined variant genotypes on risk of SPM
since any of the 4 SNPs of FAS and FASL genes in the
apoptotic pathway appeared to have a minor effect on
risk of SPM. To perform the combined analysis of all 4
SNPs, we categorized all patients into 4 groups: (1) 0–1
variant genotype group; (2) 2 variant genotype group; (3)
3 variant genotype group; and (4) 4 variant genotype
Table 1 Distribution of demographic and risk factors in the patient cohorts with index OPC and non-OPC
Variables Total OPC (N = 752) Non-OPC (N = 777)
No. SPM (N) % p* SPM (N) % p*
Total patients 1529 42 5.6 82 10.6
Age 0.004 0.024
≤Median (57 years) 770 12 28.6 33 40.2
> Median (57 years) 759 30 71.4 49 59.8
Sex 0.546 0.170
Male 1186 35 83.3 62 75.6
Female 343 7 16.7 20 24.4
Tobacco smoking 0.010 0.037
Ever 1009 22 52.4 69 84.1
Never 520 20 47.6 13 15.9
Alcohol drinking 0.813 0.005
Ever 1099 30 71.4 69 84.1
Never 430 12 28.6 13 15.9
Ethnicity 0.598 0.028
Non-Hispanic White 1333 38 90.5 60 73.2
Other 196 4 9.5 22 26.8
Index cancer stage 0.240 0.035
I or II 386 5 11.9 26 31.7
III or IV 1143 37 88.1 56 68.3
Treatmenta 0.511 0.111
S only 253 0 0.0 19 23.2
S/C/X 335 4 9.5 30 36.6
X/C 941 38 90.5 33 40.2
*χ2 test for differences between patients with and without SPM
aS, surgery, C, chemotherapy, and X, radiation
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group based on the number of variant genotypes of the 4
polymorphisms. For the combined analysis, we found that
the patients carrying 3 or 4 variant genotypes had an ap-
proximately 2-fold significantly increased risk of SPM com-
pared with those with 0–1 variant genotypes only for non-
OPC in univariate Cox analyses (cHR, 1.8 and 2.7, 95 % CI,
0.9–3.5 and 1.2–6.1, and P = 0.061 and 0.014, respectively)
and multivariable Cox analyses (aHR, 1.8 and 2.2, 95 % CI,
1.0–3.9 and 1.2–6.5, and P = 0.051 and 0.021, respectively),
while such significant associations were not found for OPC
patients (Table 3).
Stratification analysis of the combined FAS/FASL
genotypes with risk of SPM
In the stratified analysis by smoking and drinking status,
to increase statistical power, we categorized the patients
into 2 groups based on the number of combined variant
genotypes of the 4 polymorphisms (1) low-risk group
(carrying 0–2 variant genotypes) and (2) high-risk group
(carrying 3–4 variant genotypes) shown in Table 4. As
we expected, the OPC patients in high-risk group had
significantly increased risk for SPMs compared with
those in low-risk group only for never smokers (cHR;
18.9, 95 % CI; 1.3–330.2, and P = 0.032 and aHR; 20.0,
95 % CI; 1.2–327.0, and P = 0.028, respectively) but
not for ever smokers (cHR; 1.4, 95 % CI; 0.5–3.3, and
P = 0.722 and aHR; 1.4, 95 % CI; 0.6–3.4, and P = 0.787,
respectively). No such significant associations were found
for either ever drinkers or never drinkers among index
OPC patients (Table 4). However, the non-OPC patients
in high-risk group had an approximately 2-fold signifi-
cantly increased risk of SPM compared with those in
low-risk group in both ever smokers (cHR; 2.1, 95 %
CI; 1.1–4.2, P = 0.013 and aHR; 2.3, 95 % CI; 1.2–4.4,
and P = 0.011, respectively) and ever drinkers (cHR; 2.3,
95 % CI; 1.1–3.9, and P = 0.022 and aHR; 2.2, 95 % CI;
1.2–4.1, and P = 0.019, respectively), whereas such signifi-
cant associations were not observed in either never
smokers (cHR; 0.2, 95 % CI; 0.1–1.4, and P = 0.346 and
aHR; 0.1, 95 % CI; 0.0–1.2, and P = 0.323, respectively) or
never drinkers (cHR; 0.5, 95 % CI; 0.2–4.3, and P = 0.798
and aHR; 0.6, 95 % CI; 0.1–4.1, and P = 0.801, respectively).
Table 3 SPM risk associated with combined FAS/FASL variant genotypes after index OPC and non-OPC
No. variant
genotypes





OPC Non-OPC OPC Non-OPC
0-1 (ref.) 5/142 10/132 1.0 1.0 1.0 1.0
2 15/256 27/264 1.3 (0.4–3.5), 0.673 1.4 (0.6–2.7), 0.585 1.3 (0.5–3.7), 0.698 1.5 (0.5–3.3), 0.612
3 16/220 31/229 1.6 (0.6–4.1), 0.587 1.8 (0.9–3.5), 0.061 1.7 (0.5–3.8), 0.632 1.8 (1.0–3.9), 0.051
4 6/92 14/70 2.2 (0.9–6.8), 0.112 2.7 (1.2–6.1), 0.014 2.0 (0.9–6.6), 0.110 2.2 (1.2–6.5), 0.021
aCrude HRs
bHRs were adjusted for age, sex, ethnicity, smoking, alcohol, index cancer stage, and treatment
Table 2 Genotype distribution of the FAS and FASL polymorphisms among patients with index OPC and non-OPC and their
associations with risk of SPM
Variables OPC (N = 42) Non-OPC (N = 82) cHRsa (95 % CI), P Adj. HRs (95 % CI) b, P
SPM (N) % SPM (N) % OPC Non-OPC OPC Non-OPC
FAS 670 A > G
AA (ref.) 7 16.7 13 15.9 1.0 1.0 1.0 1.0
AG + GG 35 83.3 69 84.1 1.9 (0.8–4.9), 0.121 2.2 (1.2–5.7), 0.048 2.2 (0.9–5.3), 0.051 2.4 (1.1–5.1), 0.043
FAS 1377 G > A
GG (ref.) 34 80.9 64 78.0 1.0 1.0 1.0 1.0
AG + AA 8 19.1 18 22.0 0.7 (0.3–2.1), 0.435 1.1 (0.4–1.6), 0.378 0.8 (0.4–1.9), 0.476 1.0 (0.5–1.8), 0.622
FASL124 A > G
AA (ref.) 31 73.8 63 76.8 1.0 1.0 1.0 1.0
AG + GG 11 26.2 19 23.2 1.0 (0.4–2.7), 0.489 1.4 (0.7–2.8), 0.567 1.1 (0.5–2.4), 0.587 1.6 (0.9–3.0), 0.124
FASL844 C > T
CC (ref.) 11 26.2 26 31.7 1.0 1.0 1.0 1.0
CT + TT 31 73.8 56 68.3 2.5 (1.1–5.8), 0.043 1.8 (1.1–3.2), 0.041 2.7 (1.2–6.0), 0.032 1.7 (1.0–3.0), 0.049
ref.: reference group
aCrude HRs
bHRs were adjusted for age, sex, ethnicity, smoking, alcohol, index cancer stage, and treatment
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Discussion
In the present study, we evaluated the associations be-
tween the functional FAS/FASL polymorphisms and the
risk of SPMs among both index OPC versus index non-
OPC patients. We found that these polymorphisms
modified the risk of SPMs differently for index OPC
from non-OPC patients. Furthermore, when we strati-
fied the risk factors of smoking and drinking status for
further analysis, the significant associations of FAS/FASL
variant genotypes with the risk of SPM were observed
within several subgroups. These results might suggest
that genetic factors, within the context of previous or
continued exposure to smoking and alcohol may affect
the risk of SPM after index OPC and non-OPC patients.
These results support growing evidence showing that
apoptosis is associated with risk of SPMs; and tumor site
factor may contribute to this association. Thus, apop-
totic variants modify the risk of SPMs associated with
the smoking and alcohol exposure in a tumor site-
specific manner.
The roles of FAS and FASL in tumor formation have
been well studied. The down-regulation of FAS may pro-
tect tumor cells from elimination by antitumor immune
responses, whereas up-regulation of FASL may increase
the ability of tumor cells to counterattack the immune
system by inducing apoptosis of FAS-sensitive lympho-
cytes [30–33]. Therefore, alteration of the FAS and FASL
expressions may decrease the apoptotic ability of cells,
and many tumor cells may evade or suppress the
immune system. Most of the studies suggested that de-
creased FAS gene expression and/or increased FASL
gene expression is a common feature of malignant trans-
formation and an early event associated with the devel-
opment of human cancers [26, 34–42]. Survival analyses
have shown that FAS1377 and FAS670 polymorphisms
are associated with lower survival in early stage non-
small cell lung cancer patients and increased risk of re-
currence and death in epithelial ovarian cancer patients
[38, 43]. These findings support the biological plausibil-
ity that the alteration of FAS or FASL genes, such as
functional genetic polymorphisms, may affect the risk
for tumor development, including SPM.
These four polymorphisms in gene promoters may
affect function of FAS and FASL genes, and result in ex-
pression changes of these genes [26, 27, 42]. Change of
FAS or FASL expression resulting from their promoter
variants may help the transformed cells evade FAS-
mediated cell death, subsequently affecting risk for SPMs.
In the current study, we observed a significant association
between FAS670 polymorphism with risk for developing
SPMs among index non-OPC but not for OPC patients,
while a significant association of FASL844 polymorphism
with risk of SPMs among both index OPC and non-OPC
patients. These findings might suggest that there were dif-
ferent etiologies between OPC and non-OPC patients
underlying these observed associations. Although these
polymorphisms are considered to be biologically func-
tional, the findings on the association between risk of
Table 4 SPM risk associated with combined FAS/FASL variant genotypes after index OPC and non-OPC, stratified by smoking and
alcohol
Variables Low-risk groupa High-risk groupb cHRsc, (95 % CI), P aHRsd (95 % CI), P
No. % No. % Low-risk group (ref.) vs. High-risk group Low-risk group (ref.) vs. High-risk group
OPC 575 76.5 177 23.5
Smoking
Ever 325 56.5 104 58.8 1.4 (0.5–3.3), 0.722 1.4 (0.6–3.4), 0.787
Never 250 43.5 73 41.2 18.9 (1.3–330.2), 0.032 20.0 (1.2–327.0), 0.028
Alcohol
Ever 421 73.2 128 72.3 1.3 (0.3–3.7), 0.823 1.4 (0.5–3.8), 0.822
Never 154 26.8 49 27.7 1.9 (0.3–17.2), 0.887 1.8 (0.2–16.1), 0.867
Non-OPC 614 79.0 163 21.0
Smoking
Ever 455 74.1 125 76.7 2.1 (1.1–4.2), 0.013 2.3 (1.2–4.4), 0.011
Never 159 25.9 38 23.3 0.2 (0.1–1.4), 0.346 0.1 (0.0–1.2), 0.323
Alcohol
Ever 426 69.4 124 76.1 2.3 (1.1–3.9), 0.022 2.2 (1.2–4.1), 0.019
Never 188 30.6 39 23.9 0.5 (0.2–4.3), 0.798 0.6 (0.1–4.1), 0.801
aLow-risk group: 0–2 variant genotypes
bHigh-risk group: 3–4 variant genotypes
cCrude HRs
dHRs were adjusted for age, sex, ethnicity, smoking, alcohol, index cancer stage, and treatment
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SPMs and these putatively functional polymorphisms were
inconsistent. It might be likely that the study patients were
stratified by the index tumor sites, which is a potential
confounding factor when studying overall index SCCHN
patients.
Previous studies suggested that the two FAS or FASL
polymorphisms were not in a linkage disequilibrium and
these polymorphisms had a joint effect on cancer risk
[26], and the combined FAS/FASL genotypes were asso-
ciated with a significantly increased risk of SCCHN. In
the current study, such a significant association of the
combined variant genotypes of these polymorphisms
with the risk of SPM was found for non-OPC but not
for OPC. The presence and absence of the joint effect
among index OPC patients and index non-OPC might re-
sult from the different roles of FAS/FASL polymorphisms
in etiology of SPM development through gene-gene or
gene-environment (smoking, alcohol, HPV status, and
other environmental risk factors) interactions in different
site of SCCHN tissues.
Tobacco smoking, alcohol use, and HPV infection have
been well-established as risk factors for SCCHN, particu-
larly smoking/alcohol for non-OPC, and HPV for OPC.
Several studies have reported such gene-environmental in-
teractions on risk of SCCHN. A study on Taiwanese popu-
lation reported that FAS1377 and FAS670 polymorphisms
were strongly correlated with environmental factors like
cigarette smoking, betel chewing, and alcohol drinking
and had effects on increased risk of oral cancers [44]. An-
other study on Asian Indian population also found
FAS1377, FAS670, and FASL844 polymorphisms inter-
acted with tobacco smoking to increase the risk of oral
cancers [45–47]. The interaction effect between smoking
and FASL844 polymorphism on the risk was also observed
in other types of cancer, including lung, pancreatic, and
esophageal cancers [34, 36, 48, 49]. Our current study
when stratified by smoking and alcohol status showed a
consistency with the previous studies. The patients with
index non-OPC, who had the combined variant genotypes
and who were ever smokers and ever drinkers, had a sig-
nificantly higher risk for SPMs, while the patients with
OPC, who had the combined variant genotypes and who
were never smokers, had a significantly higher risk for
SPMs, but no such a significant risk was found among
ever smokers. This might be because that index non-OPC
are caused by smoking and alcohol exposure, whereas
most of index OPC patients occurs in never smokers and
are caused by HPV.
This is the first study to evaluate the associations be-
tween FAS/FASL polymorphisms and the risk for SPM
among index OPC versus non-OPC patients. Although
previous studies have found significant associations be-
tween the polymorphisms and SPM among the SCCHN
patients, they did not consider index tumor site as an
important confounding factor for such association due
to different risk factors for OPC from non-OPC patients.
Since OPC has distinguished epidemiological and clin-
ical features along with prognosis that are different from
non-OPC, it is important to investigate the associations
stratified by the tumor sites. Therefore, this current
study might provide novel information with clinician for
secondary cancer prevention and improved prognosis of
patients with primary SCCHN.
The results from such a stratified analysis by index tumor
site in the present study is essential to improving long-term
patient outcomes and accurate understanding the unique
risk factors and carcinogenesis of SCCHN at particular sub-
sites. In addition, the high frequency of SPM occurs in ap-
proximately 15 % of SCCHN patients. In patients with
SCCHN, index cancer site, HPV status, and smoking use
greatly affect the risk and distribution of SPM. Although
the incidence of SCCHN in the U.S. has been in decline
over past two decades and the diagnostic and therapeutic
approaches for the patients have been improved, the poor
prognosis for OPC and non-OPC patients has moderately
and not significantly improved, respectively. Therefore, FAS
and FASLG polymorphisms may serve as a marker for gen-
etic susceptibility to SPMs after index HPV-associated OPC
and non-HPV-associated non-OPC, and for identifying
high-risk subgroups in each cohort who might benefit from
management of alternative treatment and predictable pa-
tient outcome. Moreover, identifying markers of risk for
SPM among cancer survivors is currently limited to rather
simplistic clinical posttreatment screenings.
There are several limitations in the current study.
Firstly, a selection bias likely exists for study patients
due to the hospital-based nature of this study. Secondly,
as the rate of SPM is low in the index patient popula-
tions, the numbers of SPM event are limited the statis-
tical power in this study. After series of stratifications,
the numbers in some of the stratum or subgroups are
relatively small, thus our results may come by chance.
Thirdly, the late stage patients may have limited time for
follow-up, since those patients might not have enough
time to develop SPMs. Thus, the limited follow-up time
may bias our estimates of the associations. Furthermore,
screening bias in detecting SPM’s is not fully ruled out,
since tobacco-associated SPMs are usually easier to be
detected than non-tobacco-associated SPM. And finally,
due to the retrospective nature of the original study de-
sign, we did not have enough information on HPV infec-
tion and the continued smoking behavior after index
patient diagnosis, and these potential confounders could
also bias the observed associations.
Conclusion
FAS/FASL variants may individually or jointly modify the
risk of SPM in OPC and non-OPC differently, particularly
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in some subgroups. Further studies with larger sample size
are warranted to validate our findings; and these large
molecular epidemiological association studies also should
be considered to incorporate HPV information and smok-
ing behavior after index cancer diagnosis or treatment into
the study design.
Abbreviations
SCCHN: squamous cell carcinoma of the head and neck; SPM: second primary
malignancies; HR: hazard ratio; 95 % CI: 95 % confidence interval; HPV: human
papillomavirus; OPC: oropharyngeal cancer; non-OPC: nonoropharyngeal cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YS, WY, and WP participated in the design of the study and carried out all
the experiments and wrote the initial drafts of manuscript. EMS, DL and QW
participated in study design and manuscript preparation. WP participated in
data analysis and statistical analysis. XS, WY and GL participated in study design,
data analysis, manuscript writing, and revision. All authors read and approved
the final manuscript.
Acknowledgements
We thank Margaret Lung, Liliana Mugartegui with assistance with patient
recruitment and Ms. Yingdong Li for their help in laboratory.
Funded by
U.T. M.D. Anderson Cancer Center Start-up Funds (to E.M.S.) and National
Institute of Health Grants R01 ES-11740 and CA-131274 (to Q.W.); and N.I.H.
CA135679 (to G.L.) and CA133099 (to G.L.).
Author details
1Department of Head and Neck Surgery, Unit 1445, The University of Texas
MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston TX 77030,
USA. 2Department of Otorhinolaryngology and Head and Neck Surgery,
Yuhuangding Hospital of Qingdao University, Yantai, China. 3Key Laboratory
of Carcinogenesis and Translational Research(Ministry of Education/Beijing),
Department of Head and Neck surgery, Peking University Cancer Hospital &
Institute, Beijing, China. 4Department of Epidemiology, The University of
Texas MD Anderson Cancer Center, Houston TX 77030, USA. 5Department of
Biostatistics and Human Genetics Center, University of Texas School of Public
Health, 1200 Herman Pressler St, Houston TX 77030, USA. 6Department of
Otolaryngology, Qilu Hospital, Shandong University; Key Laboratory of
Otolaryngology, Ministry of Health, P.R. China, Jinan, Shandong 250012,
China. 7Duke Cancer Institute, Duke University Medical Center, Durham, NC
27710, USA.
Received: 28 August 2015 Accepted: 3 February 2016
References
1. Li G, Sturgis EM. The role of human papillomavirus in squamous carcinoma
of the head and neck. Curr Oncol Rep. 2006;8(2):130–9.
2. Sturgis EM, Miller RH. Second primary malignancies in the head and neck
cancer patient. Ann Otol Rhinol Laryngol. 1995;104(12):946–54.
3. Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers
after an index head and neck cancer: subsite-specific trends in the era of
human papillomavirus-associated oropharyngeal cancer. Journal of Clin
Oncol. 2011;29(6):739–46. doi:10.1200/JCO.2010.31.8311.
4. Bosetti C, Scelo G, Chuang SC, Tonita JM, Tamaro S, Jonasson JG, et al. High
constant incidence rates of second primary cancers of the head and neck: a
pooled analysis of 13 cancer registries. Int J Cancer. 2011;129(1):173–9. doi:
10.1002/ijc.25652.
5. Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A, Burgues J. Second
neoplasm in patients with head and neck cancer. Head Neck. 1999;
21(3):204–10.
6. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer.
N Engl J Med. 1993;328(3):184–94. doi:10.1056/NEJM199301213280306.
7. Ernster JA, Sciotto CG, O’Brien MM, Finch JL, Robinson LJ, Willson T, et al.
Rising incidence of oropharyngeal cancer and the role of oncogenic human
papilloma virus. Laryngoscope. 2007;117(12):2115–28. doi:10.1097/MLG.0b01
3e31813e5fbb.
8. Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, et al.
Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in
Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer.
2009;125(2):362–6. doi:10.1002/ijc.24339.
9. Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, et al. Tobacco
use in human papillomavirus-positive advanced oropharynx cancer patients
related to increased risk of distant metastases and tumor recurrence. Clin
Cancer Res. 2010;16(4):1226–35. doi:10.1158/1078-0432.CCR-09-2350.
10. Rennemo E, Zatterstrom U, Boysen M. Impact of second primary tumors on
survival in head and neck cancer: an analysis of 2,063 cases. Laryngoscope.
2008;118(8):1350–6. doi:10.1097/MLG.0b013e318172ef9a.
11. Yamamoto E, Shibuya H, Yoshimura R, Miura M. Site specific dependency of
second primary cancer in early stage head and neck squamous cell carcinoma.
Cancer. 2002;94(7):2007–14.
12. Zhang Y, Sturgis EM, Zafereo ME, Wei Q, Li G. p14ARF genetic polymorphisms
and susceptibility to second primary malignancy in patients with index
squamous cell carcinoma of the head and neck. Cancer. 2011;117(6):1227–35.
doi:10.1002/cncr.25605.
13. Day GL, Blot WJ, Shore RE, McLaughlin JK, Austin DF, Greenberg RS, et al.
Second cancers following oral and pharyngeal cancers: role of tobacco and
alcohol. J Natl Cancer Inst. 1994;86(2):131–7.
14. Do KA, Johnson MM, Lee JJ, Wu XF, Dong Q, Hong WK, et al. Longitudinal
study of smoking patterns in relation to the development of smoking-
related secondary primary tumors in patients with upper aerodigestive tract
malignancies. Cancer. 2004;101(12):2837–42. doi:10.1002/cncr.20714.
15. Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, Yang H, et al. Novel susceptibility
loci for second primary tumors/recurrence in head and neck cancer
patients: large-scale evaluation of genetic variants. Cancer Prevention Res.
2009;2(7):617–24. doi:10.1158/1940-6207.CAPR-09-0025.
16. Gal TJ, Huang WY, Chen C, Hayes RB, Schwartz SM. DNA repair gene
polymorphisms and risk of second primary neoplasms and mortality in
oral cancer patients. Laryngoscope. 2005;115(12):2221–31. doi:10.1097/01.
mlg.0000183736.96004.f7.
17. Minard CG, Spitz MR, Wu X, Hong WK, Etzel CJ. Evaluation of glutathione
S-transferase polymorphisms and mutagen sensitivity as risk factors for the
development of second primary tumors in patients previously diagnosed
with early-stage head and neck cancer. Cancer. 2006;106(12):2636–44.
doi:10.1002/cncr.21928.
18. Li F, Sturgis EM, Zafereo ME, Liu Z, Wang LE, Wei Q, et al. p73 G4C14-to-
A4T14 polymorphism and risk of second primary malignancy after index
squamous cell carcinoma of head and neck. Int J Cancer. 2009;125(11):2660–5.
doi:10.1002/ijc.24570.
19. Zafereo ME, Sturgis EM, Aleem S, Chaung K, Wei Q, Li G. Glutathione
S-transferase polymorphisms and risk of second primary malignancy after
index squamous cell carcinoma of the head and neck. Cancer Prevention
Res. 2009;2(5):432–9. doi:10.1158/1940-6207.CAPR-08-0222.
20. Zafereo ME, Sturgis EM, Liu Z, Wang LE, Wei Q, Li G. Nucleotide excision
repair core gene polymorphisms and risk of second primary malignancy in
patients with index squamous cell carcinoma of the head and neck.
Carcinogenesis. 2009;30(6):997–1002. doi:10.1093/carcin/bgp096.
21. Lei D, Sturgis EM, Liu Z, Zafereo ME, Wei Q, Li G. Genetic polymorphisms of
p21 and risk of second primary malignancy in patients with index squamous
cell carcinoma of the head and neck. Carcinogenesis. 2010;31(2):222–7.
doi:10.1093/carcin/bgp279.
22. Zornig M, Hueber A, Baum W, Evan G. Apoptosis regulators and their role in
tumorigenesis. Biochim Biophys Acta. 2001;1551(2):F1–37.
23. Thompson CB. Apoptosis in the pathogenesis and treatment of disease.
Science. 1995;267(5203):1456–62.
24. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer.
Nature. 2001;411(6835):342–8. doi:10.1038/35077213.
25. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al.
The polypeptide encoded by the cDNA for human cell surface antigen Fas
can mediate apoptosis. Cell. 1991;66(2):233–43.
26. Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, et al.
Polymorphisms of FAS and FAS ligand genes involved in the death pathway
and risk and progression of squamous cell carcinoma of the head and neck.
Clin Cancer Res. 2006;12(18):5596–602. doi:10.1158/1078-0432.CCR-05-1739.
Sun et al. BMC Cancer  (2016) 16:70 Page 8 of 9
27. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas
ligand: gene structure, chromosomal location and species specificity. Int
Immunol. 1994;6(10):1567–74.
28. Lei D, Sturgis EM, Wang LE, Liu Z, Zafereo ME, Wei Q, et al. FAS and FASLG
genetic variants and risk for second primary malignancy in patients with
squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers
Prevention. 2010;19(6):1484–91. doi:10.1158/1055-9965.EPI-10-0030.
29. Warren S, Gates O. Multiple primary malignant tumors a survey of the literature
and a statistical study. Am J Cancer. 1932;16:1358–414.
30. Reichmann E. The biological role of the Fas/FasL system during tumor
formation and progression. Semin Cancer Biol. 2002;12(4):309–15.
31. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-
induced apoptosis as a mechanism of immune privilege. Science.
1995;270(5239):1189–92.
32. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, et al. Lymphocyte
apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells–a
mechanism of immune evasion? Nat Med. 1996;2(12):1361–6.
33. Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor
gene. J Mol Med. 2000;78(6):312–25.
34. Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P, et al. Functional polymorphisms
in cell death pathway genes FAS and FASL contribute to risk of lung cancer.
J Med Genet. 2005;42(6):479–84. doi:10.1136/jmg.2004.030106.
35. Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, et al. Functional polymorphisms
in FAS and FASL contribute to increased apoptosis of tumor infiltration
lymphocytes and risk of breast cancer. Carcinogenesis. 2007;28(5):1067–73.
doi:10.1093/carcin/bgl250.
36. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death
pathway genes FAS and FASL in esophageal squamous-cell carcinoma.
J Natl Cancer Inst. 2004;96(13):1030–6.
37. Yang S, Miao XP, Zhang XM, Sun T, Qu SN, Xiong P, et al. Genetic
polymorphisms of apoptosis-associated genes FAS and FASL and risk of
colorectal cancer. Zhonghua yi xue za zhi. 2005;85(30):2132–5.
38. Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, et al. Fas
gene promoter −670 polymorphism in gynecological cancer. International
J Gynecol Cancer. 2006;16 Suppl 1:179–82. doi:10.1111/j.1525-1438.2006.
00505.x.
39. Li Y, Hao YL, Kang S, Zhou RM, Wang N, Qi BL. Genetic polymorphisms in
the Fas and FasL genes are associated with epithelial ovarian cancer risk
and clinical outcomes. Gynecol Oncol. 2013;128(3):584–9. doi:10.1016/j.ygy
no.2012.12.002.
40. Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC, et al. Genetic
polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical
carcinogenesis: An analysis of haplotype and gene-gene interaction.
Gynecol Oncol. 2005;99(1):113–8. doi:10.1016/j.ygyno.2005.05.010.
41. Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H. Re: Polymorphisms
of death pathway genes FAS and FASL in esophageal squamous-cell
carcinoma. J Natl Cancer Inst. 2004;96(19):1478–9. doi:10.1093/jnci/djh289.
author reply 9.
42. Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, et al. FASL -844C polymorphism
is associated with increased activation-induced T cell death and risk of
cervical cancer. J Exp Med. 2005;202(7):967–74. doi:10.1084/jem.20050707.
43. Park JY, Lee WK, Jung DK, Choi JE, Park TI, Lee EB, et al. Polymorphisms in
the FAS and FASL genes and survival of early stage non-small cell lung
cancer. Clin Cancer Res. 2009;15(5):1794–800. doi:10.1158/1078-0432.CCR-
08-1770.
44. Wang LH, Ting SC, Chen CH, Tsai CC, Lung O, Liu TC, et al. Polymorphisms
in the apoptosis-associated genes FAS and FASL and risk of oral cancer
and malignant potential of oral premalignant lesions in a Taiwanese
population. J Oral Pathology Med. 2010;39(2):155–61. doi:10.1111/j.1600-
0714.2009.00873.x.
45. Cao Y, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, et al. Polymorphisms
of death pathway genes FAS and FASL and risk of nasopharyngeal
carcinoma. Mol Carcinog. 2010;49(11):944–50. doi:10.1002/mc.20676.
46. Karimi MY, Kapoor V, Sharma SC, Das SN. Genetic polymorphisms in FAS
(CD95) and FAS ligand (CD178) promoters and risk of tobacco-related oral
carcinoma: gene-gene interactions in high-risk Indians. Cancer Invest.
2013;31(1):1–6. doi:10.3109/07357907.2012.743555.
47. Wang J, Gao J, Li Y, Zhao X, Gao W, Peng L, et al. Functional polymorphisms
in FAS and FASL contribute to risk of squamous cell carcinoma of the larynx
and hypopharynx in a Chinese population. Gene. 2013;524(2):193–6.
doi:10.1016/j.gene.2013.04.034.
48. Souza RF, Shewmake K, Pearson S, Sarosi Jr GA, Feagins LA, Ramirez RD,
et al. Acid increases proliferation via ERK and p38 MAPK-mediated increases
in cyclooxygenase-2 in Barrett’s adenocarcinoma cells. Am J Physiol Gastrointest
Liver Physiol. 2004;287(4):G743–8. doi:10.1152/ajpgi.00144.2004.
49. Yang M, Sun T, Wang L, Yu D, Zhang X, Miao X, et al. Functional variants in
cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res.
2008;14(10):3230–6. doi:10.1158/1078-0432.CCR-08-0177.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Sun et al. BMC Cancer  (2016) 16:70 Page 9 of 9
